• CytomX Therapeutics to Present at Upcoming August Investor Conferences

    Источник: Nasdaq GlobeNewswire / 02 авг 2021 08:00:01   America/New_York

    SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual investor conferences in August.

    BTIG 5th Virtual Biotechnology Conference
    Date: Monday, August 9, 2021
    Presentation Time: 1:00 p.m. ET.

    2021 Wedbush PacGrow Healthcare Virtual Conference
    Date: Tuesday, August 10, 2021
    Panel Discussion: 1:10 p.m. ET

    In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

    About CytomX Therapeutics
    CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.

    Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment. As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential first-in-class therapeutic candidates against novel, difficult to drug targets and potential best-in-class immunotherapeutic candidates against clinically validated targets. The CytomX clinical-stage pipeline comprises five assets, four of which are in Phase 2 clinical studies. First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues. The CytomX clinical-stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probodies, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab (CX-072). For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter.

    Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

    Investor Contact:
    Chau Cheng, PhD MBA
    VP, Investor Relations & Corp. Communications
    ccheng@cytomx.com
    Direct: (650) 273-4999

    Media Contact:
    Bret Coons
    Director, Corporate Communications
    bcoons@cytomx.com
    Direct: (650) 528 2929 


    Primary Logo

Опубликовать